Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALLERFED vs ADVIL CONGESTION RELIEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALLERFED is a combination of an antihistamine (fexofenadine) and a decongestant (pseudoephedrine). Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine effects, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor activation, causing vasoconstriction of nasal mucosa.
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
Seasonal allergic rhinitis,Perennial allergic rhinitis,Nasal congestion associated with allergies
temporary relief of nasal congestion,sinus pressure,headache,fever,minor aches and pains associated with common cold or flu
1 tablet (pseudoephedrine 60 mg / triprolidine 2.5 mg) orally every 4-6 hours; not to exceed 4 doses per 24 hours.
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
Terminal elimination half-life 20-24 hours; clinically significant for once-daily dosing in seasonal allergic rhinitis.
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
Fexofenadine is minimally metabolized (<5%) in the liver; primarily excreted unchanged in feces (80%) and urine (11%). Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted mostly unchanged in urine.
ibuprofen: primarily hepatic via CYP2C9; phenylephrine: primarily hepatic via monoamine oxidase (MAO) and sulfation
Primarily renal (approximately 60-70% as unchanged drug and metabolites); minor biliary (10-15%); fecal (5-10%).
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
80-85% bound to albumin and alpha-1-acid glycoprotein.
Ibuprofen: >99% bound to albumin. Pseudoephedrine: 20-30% bound to albumin.
Vd 5-7 L/kg, indicating extensive tissue distribution beyond plasma volume.
Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution).
Oral: 40-50% due to first-pass metabolism; intranasal: 70-80%.
Oral: Ibuprofen ~80-100% (high), Pseudoephedrine ~100% (high).
Cr Cl 30-50 m L/min: administer every 6-8 hours. Cr Cl 10-29 m L/min: administer every 8-12 hours. Cr Cl <10 m L/min: not recommended.
Avoid use if Cr Cl <30 m L/min. For Cr Cl 30-59 m L/min, use lowest effective dose and shortest duration.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% or extend interval. Child-Pugh Class C: avoid use.
Avoid use in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use with caution and at the lowest effective dose.
Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg / triprolidine 1.25 mg) orally every 4-6 hours; max 2 doses per 24 hours. Children <6 years: not recommended.
Not recommended in children under 12 years of age due to phenylephrine component. For children 12 years and older, same as adult dosing.
Initiate at half the adult dose; monitor for anticholinergic effects, dizziness, and hypertension; maximum 2 doses per 24 hours.
Start at the low end of dosing range; avoid use in patients 65 years and older if possible due to increased risk of adverse effects; if necessary, use lowest effective dose for shortest duration.
None.
ibuprofen carries a black box warning for increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal, and for serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines
Severe hypertension,Coronary artery disease,Ischemic heart disease,Increased intraocular pressure,Diabetes,Thyroid disease,Prostatic hypertrophy,Renal impairment,Use with caution in elderly,Avoid with MAOIs or within 14 days of stopping
cardiovascular risk,gastrointestinal risk,renal effects,avoid concomitant use of other NSAIDs,hypertension,hyperthyroidism,diabetes,heart disease,use with MAOIs may cause hypertensive crisis
Hypersensitivity to any component,Severe hypertension,Severe coronary artery disease,Use with or within 14 days of MAOIs,Narrow-angle glaucoma,Urinary retention,Severe renal impairment (Cr Cl <30 m L/min)
hypersensitivity to ibuprofen, phenylephrine, or any component,history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs,perioperative pain in setting of coronary artery bypass graft (CABG) surgery,severe hypertension,severe coronary artery disease,use of MAOIs or within 14 days of stopping MAOIs
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented foods) if taking MAOIs concurrently. Grapefruit juice may increase absorption of triprolidine. Caffeine may enhance stimulant effects of pseudoephedrine.
Avoid alcohol consumption due to increased risk of GI bleeding and liver damage. No specific food interactions; take with food or milk to reduce stomach upset. Caffeine may exacerbate pseudoephedrine's stimulant effects; limit caffeine intake.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest possible increased risk of minor malformations. Second/third trimester: Use associated with reduced uterine blood flow and fetal tachycardia; avoid near term due to risk of prolonged QT interval in neonate.
First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and premature ductus arteriosus constriction. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Phenylephrine: Limited human data; animal studies show fetal abnormalities at high doses; avoid in first trimester due to potential vascular disruption.
Excreted in breast milk with M/P ratio of approximately 0.5. American Academy of Pediatrics considers compatible with breastfeeding; however, use with caution due to potential for irritability and drowsiness in infant.
Ibuprofen: Excreted into breast milk in low amounts (M/P ratio ~0.07). Compatible with breastfeeding; minimal infant exposure. Phenylephrine: Not known if excreted in breast milk; M/P ratio unknown. Avoid due to potential for infant hypertension and irritability. Alternative decongestants preferred.
Increased plasma volume and renal clearance in pregnancy may reduce drug concentrations; however, specific dose adjustment is not routinely recommended due to limited data. Use lowest effective dose for shortest duration.
Pharmacokinetic changes in pregnancy: Increased volume of distribution and clearance for ibuprofen may require higher doses, but avoid due to fetal risks. No standard dose adjustment recommended; use lowest effective dose for shortest duration. Phenylephrine: No specific dosing adjustments in pregnancy; avoid use due to limited safety data.
Allerfed combines pseudoephedrine and triprolidine. Use with caution in hypertension, cardiovascular disease, and glaucoma. Avoid in patients with severe hypertension or coronary artery disease. Limit duration to 5-7 days to avoid rebound congestion. Anticholinergic effects may cause urinary retention in BPH.
Advil Congestion Relief combines ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen can cause nephrotoxicity; pseudoephedrine can elevate blood pressure and heart rate. Avoid in patients with uncontrolled hypertension, severe CAD, or MAOI use within 14 days. Use with caution in elderly due to increased risk of GI bleeding and CNS effects. Not recommended for children under 12 years.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose; avoid taking more than every 4-6 hours.,Avoid alcohol while taking this medication.,If symptoms persist for more than 7 days, consult your doctor.,May cause drowsiness; avoid driving or operating heavy machinery until you know how you react.
Do not take more than directed; do not use with other products containing ibuprofen or other NSAIDs (e.g., naproxen, aspirin) due to increased risk of stomach bleeding.,Avoid alcohol while taking this medication to reduce the risk of stomach irritation and bleeding.,Pseudoephedrine may cause insomnia, nervousness, or dizziness; take the last dose at least 4-6 hours before bedtime.,Stop use and consult a doctor if symptoms persist after 5 days (fever >3 days), if new symptoms appear, or if you experience signs of stomach bleeding (black/bloody stools, vomit with blood/coffee-grounds).,Do not use if you have heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or difficulty urinating due to an enlarged prostate unless directed by a doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALLERFED vs ADVIL CONGESTION RELIEF, answered by our medical review team.
ALLERFED is a Decongestant that works by ALLERFED is a combination of an antihistamine (fexofenadine) and a decongestant (pseudoephedrine). Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine effects, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor activation, causing vasoconstriction of nasal mucosa.. ADVIL CONGESTION RELIEF is a NSAID/Decongestant Combination that works by ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALLERFED and ADVIL CONGESTION RELIEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALLERFED is: 1 tablet (pseudoephedrine 60 mg / triprolidine 2.5 mg) orally every 4-6 hours; not to exceed 4 doses per 24 hours.. The standard adult dose of ADVIL CONGESTION RELIEF is: 1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALLERFED and ADVIL CONGESTION RELIEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALLERFED is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest possible increased risk of minor malformations. Second/third trimester: Use associated with re. ADVIL CONGESTION RELIEF is classified as Category C. First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.